

Amendments to the Claims

No amendments to the claims have been made.

Listing of the Claims

This listing of the claims replaces all other listings of the claims in the application:

1. (Previously Presented) A dosage form useful in ophthalmic treatment having a predetermined liquid volume of from about 3 to 20 μl , the dosage form being a jet or stream of droplets of treatment fluid, each droplet having an ophthalmologically active compound in suspension or solution and wherein the jet or each droplet of a size sufficient to sustain momentum along a substantially horizontal path 5 cms in length from a discharge velocity of up to 25 m/sec from the delivery device, wherein substantially the entire dosage form is delivered to the target site and where the jet or stream of droplets is a moving volume of liquid droplets, where the volume has a length and diameter that remain substantially unchanged between exiting the delivery device and contacting the target site.
2. (Original) A dosage form according to claim 1 wherein the jet or each droplet has the active compound in aqueous suspension or solution.
3. (Canceled).
4. (Canceled).
5. (Previously Presented) A dosage form according to claim 1 wherein the jet or each droplet has a diameter in the range 100 to 800 μm .
6. (Original) A dosage form according to claim 5 wherein the jet or each droplet has a diameter in the range 200 to 400 μm .
7. (Previously Presented) A dosage form according to claim 1 in which the total volume of treatment fluid does not exceed 10 μl .
8. (Original) A dosage form according to claim 7 in which the total volume of treatment fluid is in the range 3 to 8 μl .
9. (Previously Presented) A method of ophthalmic treatment comprising delivering to an eye a dosage form according to claim 1.
10. (Original) A method according to claim 9 wherein the eye is a human eye.
11. (Previously Presented) A method according to claim 9 wherein the dosage form is directed at a particular site in the eye.

12. (Previously Presented) A method of increasing the ocular bioavailability of ophthalmologically active compound, wherein the compound is provided in suspension or solution in a body of ophthalmic treatment liquid in a dosage form comprising the liquid as a jet and/or stream of droplets, the jet and/or each droplet being of a size sufficient to sustain momentum in transmission from a delivery device to a target site within an eye, the jet and/or droplets having a mean diameter in the range 20 μm to 1000 μm .
13. (Previously Presented) A method according to claim 12 wherein the mean diameter of the jet and/or droplets is in the range 100 μm to 800 μm .
14. (Previously Presented) A method according to claim 12 wherein the total volume of treatment liquid in the dosage form does not exceed 10 μl .
15. (Original) A method according to claim 14 wherein the total volume of treatment liquid in the dosage form is in the range 3 μl to 8 μl .
16. (Previously Presented) A dosage form according to claim 3 wherein the jet or each droplet has a diameter in the range 100 to 800 μm .
17. (Previously Presented) A dosage form according to claim 3 wherein the jet or each droplet has a diameter in the range 200 to 400 μm .
18. (Previously Presented) A dosage form according to claim 17 in which the total volume of treatment fluid does not exceed 10 μl .
19. (Previously Presented) A method of ophthalmic treatment comprising delivering to an eye a dosage form according to claim 8.
20. (Previously Presented) A method according to claim 12 wherein the mean diameter of the jet and/or droplets is in the range of 200 μm to 400 μm .